MMJ increases stake in Sequoya
Published 16-APR-2020 11:03 A.M.
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MMJ Group Holdings Limited (ASX: MMJ/OTC: MMJJF), an Australian-listed company that specialises in managing a portfolio of investments along the cannabis value-chain, has agreed to provide a C$2.5 million secured convertible note facility to Sequoya Cannabis Limited.
This may be drawn down in tranches at MMJ’s option.
MMJ has advanced an initial C$350,000 to Sequoya under the convertible note facility.
The company secured this additional investment opportunity by exercising a right secured in July 2019 to invest up to a further C$2.5 million in Sequoya to finance the company’s business plan.
The Initial Advance was funded from the proceeds of the MMJ Share Purchase Plan completed on 24 March, 2020.
Following receipt of the Initial Advance, Sequoya’s Polish subsidiary, Sequoya Europe, is expected to commence production of CBD extracts and isolate in April 2020 at its European Union GMP Certified production facility.
Only EU GMP certified hemp extraction facility in Europe
The Sequoya facility is built from the ground up with the strictest production, quality and safety standards, allowing quick and smooth certification of the entire facility and it marks the only complete end-to-end EU GMP certified hemp extraction facility in Europe.
The facility includes a modern, fully equipped analysis and quality control area, staffed with senior research and development and quality specialists ensuring tight control over producing consistent and highest quality results.
With few regulatory hurdles around CBD in Europe, Sequoya is receiving strong interest from consumer goods manufacturers, namely cosmetics, food, beverage and nutraceutical companies.
With the financial backing of MMJ, Sequoya is now able to move to the next step to become a significant GMP-certified hemp CBD supplier, with longer term plans to expand into the legal medicinal marijuana market across Europe.
MMJ anticipates excellent investment returns
MMJ has identified a number of factors that should result in the Sequoya investment delivering outstanding returns.
Importantly, Sequoya is focusing on extraction, which is the highest value opportunity within the cannabis ecosystem and it has built a large-scale production plant in a low-cost jurisdiction which has easy no-tariff access to high value markets such as Germany and Northern Europe.
As the industry evolves, the ability to produce GMP certified product at a lower cost in Europe will be a strategic advantage for Sequoya.
Poland also provides access to world class technicians and engineers at a substantially lower cost than available elsewhere, some of whom are already working with Sequoya.
MMJ has also secured the rights to make further investments in Sequoya.
These include the exercise of warrants that provide the option for MMJ to acquire a further 1.25 million shares at C0.075 each following conversion of the July 2019 Note for a period of two years following the date of conversion.
MMJ can also exercise warrants that provide it with the option to acquire one share at C0.10 each for each two Sequoya shares received following conversion of the April 2020 Note for a period of two years following the date of conversion.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.